Pulmonary drug delivery: A role for polymeric nanoparticles?

Current Topics in Medicinal Chemistry

Volumn 15, Issue 4, 2015, Pages 386-400

  D’Angelo, Ivana ^a   Conte, Claudia ^b   Miro, Agnese ^b   Quaglia, Fabiana ^b   Ungaro, Francesca ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Biodegradable polymers; Biological barriers; Nanoparticles; Natural polymers; Pulmonary delivery

Indexed keywords

ALGINIC ACID; BORTEZOMIB; CALCITONIN; CHITOSAN; CISPLATIN; FLUOROURACIL; HEXADECANOL; INSULIN; ISONIAZID; LACTOSE; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL; MANNITOL; MUCIN; NANOPARTICLE; PIRFENIDONE; PLASMID DNA; POLYETHYLENEIMINE; POLYLACTIC ACID; POLYMERIC NANOPARTICLE; PYRAZINAMIDE; QUERCETIN; RIFAMPICIN; SALBUTAMOL; SALCATONIN; SMALL INTERFERING RNA; TOBRAMYCIN; TRIPALMITIN; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; VORICONAZOLE; POLYMER;

AEROSOL; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; DEFENSE MECHANISM; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRY POWDER INHALER; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG INFECTION; METERED DOSE INHALER; MINIMUM INHIBITORY CONCENTRATION; NANOTOXICOLOGY; NEBULIZATION; PARTICLE SIZE; PROTEIN DEGRADATION; PULMONARY DRUG DELIVERY; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM;

ADMINISTRATION, INHALATION; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; NANOPARTICLES; POLYMERS;

EID: 84940477685     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150108123256     Document Type: Article

References (129)

1. Patton, J.S.; McCabe, J.G.; Hansen, S.E.; Daugherty, A.L. Absorption of human growth hormone from the rat lung. Biotechnol. Ther., 1989, 1, 213-228.
2. Loira-Pastoriza, C.; Todoroff, J.; Vanbever, R. Delivery strategies for sustained drug release in the lungs. Adv. Drug Deliv. Rev., 2014, 75C, 81-91.
3. Sung, J.C.; Pulliam, B.L.; Edwards, D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol., 2007, 25, 563-570.
4. Patton, J.S.; Byron, P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov., 2007, 6, 67-74.
5. Paranjpe, M.; Muller-Goymann, C.C. Nanoparticle-mediated pulmonary drug delivery: a review. Int. J. Mol. Sci., 2014, 15, 5852-5873.
6. Emami, J.; Pourmashhadi, A.; Sadeghi, H.; Varshosaz, J.; Hamishehkar, H. Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and their in vitro cytotoxicity for lung cancer therapy. Pharm. Dev. Technol., 2014, 1-10.
7. Das, J.; Das, S.; Paul, A.; Samadder, A.; Bhattacharyya, S.S.; Khuda-Bukhsh, A.R. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo. Toxicol. Lett., 2014, 225, 454-466.
8. Ensign, L.M.; Schneider, C.; Suk, J.S.; Cone, R.; Hanes, J. Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv. Mater., 2012, 24, 3887-3894.
9. Sigurdsson, H.H.; Kirch, J.; Lehr, C.M. Mucus as a barrier to lipophilic drugs. Int. J. Pharm., 2013, 453, 56-64.
10. Labiris, N.R.; Dolovich, M.B. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol., 2003, 56, 588-599.
11. Patton, J.S.; Fishburn, C.S.; Weers, J.G. The lungs as a portal of entry for systemic drug delivery. Proc. Am. Thorac. Soc., 2004, 1, 338-344.
12. Brand, P.; Schulte, M.; Wencker, M.; Herpich, C.H.; Klein, G.; Hanna, K.; Meyer, T. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur. Respir. J., 2009, 34, 354-360.
13. Dolovich, M.B.; Dhand, R. Aerosol drug delivery: developments in device design and clinical use. Lancet, 2011, 377, 1032-1045.
14. S. Newman, P. Anderson, P. Byron, R. Dalby, J. Peart, Respiratory Drug Delivery: Essential Theory & Practice. RDD Online, Richmond (VA), 2009.
15. Carvalho, T.C.; Peters, J.I.; Williams, R.O., III. Influence of particle size on regional lung deposition--what evidence is there? Int. J. Pharm., 2011, 406, 1-10.
16. Heyder, J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc. Am. Thorac. Soc., 2004, 1, 315-320.
17. Cone, R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev., 2009, 61, 75-85.
18. Sanders, N.; Rudolph, C.; Braeckmans, K.; De Smedt, S.C.; Demeester, J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev., 2009, 61, 115-127.
19. Widdicombe, J.G. Airway liquid: a barrier to drug diffusion? European Respiratory Journal, 1997, 10, 2194-2197.
20. Lai, S.K.; Wang, Y.Y.; Wirtz, D.; Hanes, J. Micro- and macrorheology of mucus. Adv. Drug Deliv. Rev., 2009, 61, 86-100.
21. Pelletier, O.; Pokidysheva, E.; Hirst, L.S.; Bouxsein, N.; Li, Y.; Safinya, C.R. Structure of actin cross-linked with alpha-actinin: a network of bundles. Phys. Rev. Lett., 2003, 91, 148102.
22. Smaldone, G.C.; Foster, W.M.; O'Riordan, T.G.; Messina, M.S.; Perry, R.J.; Langenback, E.G. Regional impairment of mucociliary clearance in chronic obstructive pulmonary disease. Chest, 1993, 103, 1390-1396.
23. Hussell, T.; Bell, T.J. Alveolar macrophages: plasticity in a tissuespecific context. Nat. Rev. Immunol., 2014, 14, 81-93.
24. Ibrahim, B.M.; Park, S.; Han, B.; Yeo, Y. A strategy to deliver genes to cystic fibrosis lungs: a battle with environment. J. Control Release., 2011, 155, 289-295.
25. Ungaro, F.; d'Angelo, I.; Miro, A.; La Rotonda, M.I.; Quaglia, F. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. J. Pharm. Pharmacol., 2012, 64, 1217-1235.
26. Gagnadoux, F.; Hureaux, J.; Vecellio, L.; Urban, T.; Le, P.A.; Valo, I.; Montharu, J.; Leblond, V.; Boisdron-Celle, M.; Lerondel, S.; Majoral, C.; Diot, P.; Racineux, J.L.; Lemarie, E. Aerosolized chemotherapy. J. Aerosol Med. Pulm. Drug Deliv., 2008, 21, 61-70.
27. Lam, J.K.; Liang, W.; Chan, H.K. Pulmonary delivery of therapeutic siRNA. Adv. Drug Deliv. Rev., 2012, 64, 1-15.
28. Hillaireau, H.; Couvreur, P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol. Life Sci., 2009, 66, 2873-2896.
29. Daniels, T.; Mills, N.; Whitaker, P. Nebuliser systems for drug delivery in cystic fibrosis. Paediatr. Respir. Rev., 2013, 14, 98-99.
30. Rogueda, P.G.; Traini, D. The nanoscale in pulmonary delivery. Part 2: formulation platforms. Expert. Opin. Drug Deliv., 2007, 4, 607-620.
31. Pulliam, B.; Sung, J.C.; Edwards, D.A. Design of nanoparticlebased dry powder pulmonary vaccines. Expert Opin. Drug Deliv., 2007, 4, 651-663.
32. Al-Hallak, M.H.; Sarfraz, M.K.; Azarmi, S.; Roa, W.H.; Finlay, W.H.; Lobenberg, R. Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. Ther. Deliv., 2011, 2, 1313-1324.
33. Lai, S.K.; Wang, Y.Y.; Hanes, J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev., 2009, 61, 158-171.
34. Aljayyoussi, G.; Abdulkarim, M.; Griffiths, P.; Gumbleton, M. Pharmaceutical nanoparticles and the mucin biopolymer barrier. Bioimpacts., 2012, 2, 173-174.
35. Henning, A.; Schneider, M.; Nafee, N.; Muijs, L.; Rytting, E.; Wang, X.; Kissel, T.; Grafahrend, D.; Klee, D.; Lehr, C.M. Influence of particle size and material properties on mucociliary clearance from the airways. J. Aerosol Med. Pulm. Drug Deliv., 2010, 23, 233-241.
36. Kirch, J.; Guenther, M.; Doshi, N.; Schaefer, U.F.; Schneider, M.; Mitragotri, S.; Lehr, C.M. Mucociliary clearance of micro- and nanoparticles is independent of size, shape and charge--an ex vivo and in silico approach. J. Control Release., 2012, 159, 128-134.
37. Ungaro, F.; d'Angelo, I.; Coletta, C.; d’Emmanuele, V; Sorrentino, R.; Perfetto, B.; Tufano, M.A.; Miro, A.; La Rotonda, M.I.; Quaglia, F. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J. Control Release., 2012, 157, 149-159.
38. Wang, Y.Y.; Lai, S.K.; So, C.; Schneider, C.; Cone, R.; Hanes, J. Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure. PLoS One, 2011, 6, e21547.
39. Yamamoto, H.; Kuno, Y.; Sugimoto, S.; Takeuchi, H.; Kawashima, Y. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J. Control Release., 2005, 102, 373-381.
40. Hoiby, N.; Ciofu, O.; Bjarnsholt, T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiology, 2010, 5, 1663-1674.
41. d'Angelo, I.; Conte, C.; La Rotonda, M.I.; Miro, A.; Quaglia, F.; Ungaro, F. Improving the efficacy of inhaled drugs in cystic fibrosis: Challenges and emerging drug delivery strategies. Adv. Drug Deliv. Rev., 2014, 75C, 92-111.
42. Forier, K.; Messiaen, A.S.; Raemdonck, K.; Deschout, H.; Rejman, J.; De, B.F.; Nelis, H.; De Smedt, S.C.; Demeester, J.; Coenye, T.; Braeckmans, K. Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy. Nanomedicine. (Lond), 2013, 8, 935-949.
43. Messiaen, A.S.; Forier, K.; Nelis, H.; Braeckmans, K.; Coenye, T. Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms. PLoS. One., 2013, 8, e79220.
44. Hitzman, C.J.; Elmquist, W.F.; Wiedmann, T.S. Development of a respirable, sustained release microcarrier for 5-fluorouracil II: In vitro and in vivo optimization of lipid coated nanoparticles. J. Pharm. Sci., 2006, 95, 1127-1143.
45. Hitzman, C.J.; Wattenberg, L.W.; Wiedmann, T.S. Pharmacokinetics of 5-fluorouracil in the hamster following inhalation delivery of lipid-coated nanoparticles. J. Pharm. Sci., 2006, 95, 1196-1211.
46. Issa, M.M.; Koping-Hoggard, M.; Tommeraas, K.; Varum, K.M.; Christensen, B.E.; Strand, S.P.; Artursson, P. Targeted gene delivery with trisaccharide-substituted chitosan oligomers in vitro and after lung administration in vivo. J. Control Release, 2006, 115, 103-112.
47. Bivas-Benita, M.; Lin, M.Y.; Bal, S.M.; van Meijgaarden, K.E.; Franken, K.L.; Friggen, A.H.; Junginger, H.E.; Borchard, G.; Klein, M.R.; Ottenhoff, T.H. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine, 2009, 27, 4010-4017.
48. Fahmy, T.M.; Demento, S.L.; Caplan, M.J.; Mellman, I.; Saltzman, W.M. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine. (Lond), 2008, 3, 343-355.
49. Ossipov, D.A. Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin. Drug Deliv., 2010, 7, 681-703.
50. Tseng, C.L.; Wang, T.W.; Dong, G.C.; Yueh-Hsiu, W.S.; Young, T.H.; Shieh, M.J.; Lou, P.J.; Lin, F.H. Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials, 2007, 28, 3996-4005.
51. Tseng, C.L.; Su, W.Y.; Yen, K.C.; Yang, K.C.; Lin, F.H. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation. Biomaterials, 2009, 30, 3476-3485.
52. Choi, K.Y.; Saravanakumar, G.; Park, J.H.; Park, K. Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf. B Biointerfaces, 2012, 99, 82-94.
53. Dames, P.; Gleich, B.; Flemmer, A.; Hajek, K.; Seidl, N.; Wiekhorst, F.; Eberbeck, D.; Bittmann, I.; Bergemann, C.; Weyh, T.; Trahms, L.; Rosenecker, J.; Rudolph, C. Targeted delivery of magnetic aerosol droplets to the lung. Nat. Nanotechnol., 2007, 2, 495-499
54. Verma, N.K.; Crosbie-Staunton, K.; Satti, A.; Gallagher, S.; Ryan, K.B.; Doody, T.; McAtamney, C.; MacLoughlin, R.; Galvin, P.; Burke, C.S.; Volkov, Y.; Gun'ko, Y.K. Magnetic core-shell nanoparticles for drug delivery by nebulization. J. Nanobiotechnology., 2013, 11, 1.
55. Mehanna, M.M.; Mohyeldin, S.M.; Elgindy, N.A. Respirable nanocarriers as a promising strategy for antitubercular drug delivery. J. Control Release, 2014, 187, 183-197.
56. Moretton, M.A.; Chiappetta, D.A.; Andrade, F.; das, N.J.; Ferreira, D.; Sarmento, B.; Sosnik, A. Hydrolyzed galactomannan-modified nanoparticles and flower-like polymeric micelles for the active targeting of rifampicin to macrophages. J. Biomed. Nanotechnol., 2013, 9, 1076-1087.
57. Kunda, N.K.; Somavarapu, S.; Gordon, S.B.; Hutcheon, G.A.; Saleem, I.Y. Nanocarriers targeting dendritic cells for pulmonary vaccine delivery. Pharm. Res., 2013, 30, 325-341.
58. Irache, J.M.; Salman, H.H.; Gamazo, C.; Espuelas, S. Mannosetargeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv., 2008, 5, 703-724.
59. Shoyele, S.A.; Cawthorne, S. Particle engineering techniques for inhaled biopharmaceuticals. Adv. Drug Deliv. Rev., 2006, 58, 1009-1029.
60. Rytting, E.; Nguyen, J.; Wang, X.; Kissel, T. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin. Drug Deliv., 2008, 5, 629-639.
61. Kurmi, B.D.; Kayat, J.; Gajbhiye, V.; Tekade, R.K.; Jain, N.K. Micro- and nanocarrier-mediated lung targeting. Expert Opin. Drug Deliv., 2010, 7, 781-794.
62. Wang, J.J.; Zeng, Z.W.; Xiao, R.Z.; Xie, T.; Zhou, G.L.; Zhan, X.R.; Wang, S.L. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomedicine., 2011, 6, 765-774.
63. Garg, N.K.; Mangal, S.; Khambete, H.; Tyagi, R.K. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers. Recent Pat Drug Deliv. Formul., 2010, 4, 114-128.
64. Menon, J.U.; Ravikumar, P.; Pise, A.; Gyawali, D.; Hsia, C.C.W.; Nguyen, K.T. Polymeric nanoparticles for pulmonary protein and DNA delivery. Acta Biomaterialia, 2014, 10, 2643-2652.
65. Garcia-Fuentes, M.; Alonso, M.J. Chitosan-based drug nanocarriers: where do we stand? J. Control Release, 2012, 161, 496-504.
66. Trapani, A.; Di Gioia, S.; Ditaranto, N.; Cioffi, N.; Goycoolea, F.M.; Carbone, A.; Garcia-Fuentes, M.; Conese, M.; Alonso, M.J. Systemic heparin delivery by the pulmonary route using chitosan and glycol chitosan nanoparticles. International Journal of Pharmaceutics, 2013, 447, 115-123.
67. Makhlof, A.; Werle, M.; Tozuka, Y.; Takeuchi, H. Nanoparticles of glycol chitosan and its thiolated derivative significantly improved the pulmonary delivery of calcitonin. Int. J. Pharm., 2010, 397, 92-95.
68. Al-Qadi, S.; Grenha, A.; Carrion-Recio, D.; Seijo, B.; Remunan- Lopez, C. Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations. J. Control Release, 2012, 157, 383-390.
69. Helander, I.M.; Nurmiaho-Lassila, E.L.; Ahvenainen, R.; Rhoades, J.; Roller, S. Chitosan disrupts the barrier properties of the outer membrane of gram-negative bacteria. Int. J. Food Microbiol., 2001, 71, 235-244.
70. Du, W.L.; Niu, S.S.; Xu, Y.L.; Xu, Z.R.; Fan, C.L. Antibacterial activity of chitosan tripolyphosphate nanoparticles loaded with various metal ions. Carbohydrate Polymers, 2009, 75, 385-389.
71. Friedman, A.J.; Phan, J.; Schairer, D.O.; Champer, J.; Qin, M.; Pirouz, A.; Blecher-Paz, K.; Oren, A.; Liu, P.T.; Modlin, R.L.; Kim, J. Antimicrobial and anti-inflammatory activity of chitosanalginate nanoparticles: a targeted therapy for cutaneous pathogens. J. Invest Dermatol., 2013, 133, 1231-1239.
72. Zahoor, A.; Sharma, S.; Khuller, G.K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. International Journal of Antimicrobial Agents, 2005, 26, 298-303.
73. Thomas, C.; Rawat, A.; Hope-Weeks, L.; Ahsan, F. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol. Pharm., 2011, 8, 405-415.
74. Amini, M.A.; Faramarzi, M.A.; Gilani, K.; Moazeni, E.; Esmaeilzadeh-Gharehdaghi, E.; Amani, A. Production, characterisation, and in vitro nebulisation performance of budesonide-loaded PLA nanoparticles. J. Microencapsul., 2014, 31, 422-429.
75. Lemoine, D.; Francois, C.; Kedzierewicz, F.; Preat, V.; Hoffman, M.; Maincent, P. Stability study of nanoparticles of poly(epsiloncaprolactone), poly(D,L-lactide) and poly(D,L-lactide-coglycolide). Biomaterials, 1996, 17, 2191-2197.
76. Mundargi, R.C.; Babu, V.R.; Rangaswamy, V.; Patel, P.; Aminabhavi, T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Control Release, 2008, 125, 193-209.
77. das, N.J.; Bahia, M.F.; Amiji, M.M.; Sarmento, B. Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale. Expert Opin. Drug Deliv., 2011, 8, 1085-1104.
78. Yang, M.; Yamamoto, H.; Kurashima, H.; Takeuchi, H.; Yokoyama, T.; Tsujimoto, H.; Kawashima, Y. Design and evaluation of inhalable chitosan-modified poly (DL-lactic-coglycolic acid) nanocomposite particles. Eur. J. Pharm. Sci., 2012, 47, 235-243.
79. Lee, C.; Choi, J.S.; Kim, I.; Oh, K.T.; Lee, E.S.; Park, E.S.; Lee, K.C.; Youn, Y.S. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes. Int. J. Nanomedicine, 2013, 8, 2975-2983.
80. Mert, O.; Lai, S.K.; Ensign, L.; Yang, M.; Wang, Y.Y.; Wood, J.; Hanes, J. A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles. J. Control Release, 2012, 157, 455-460.
81. Vij, N.; Min, T.; Marasigan, R.; Belcher, C.N.; Mazur, S.; Ding, H.; Yong, K.T.; Roy, I. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J. Nanobiotechnology., 2010, 8, 22.
82. Yang, M.; Lai, S.K.; Yu, T.; Wang, Y.Y.; Happe, C.; Zhong, W.; Zhang, M.; Anonuevo, A.; Fridley, C.; Hung, A.; Fu, J.; Hanes, J. Nanoparticle penetration of human cervicovaginal mucus: The effect of polyvinyl alcohol. J. Control Release, 2014, 192, 202-208.
83. Mathaes, R.; Winter, G.; Besheer, A.; Engert, J. Influence of particle geometry and PEGylation on phagocytosis of particulate carriers. Int. J. Pharm., 2014, 465, 159-164.
84. Andrade, F.; Rafael, D.; Videira, M.; Ferreira, D.; Sosnik, A.; Sarmento, B. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv. Drug Deliv. Rev., 2013, 65, 1816-1827.
85. Pandey, R.; Sharma, A.; Zahoor, A.; Sharma, S.; Khuller, G.K.; Prasad, B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother., 2003, 52, 981-986.
86. Ohashi, K.; Kabasawa, T.; Ozeki, T.; Okada, H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control Release, 2009, 135, 19-24.
87. Jurek, S.C.; Hirano-Kobayashi, M.; Chiang, H.; Kohane, D.S.; Matthews, B.D. Prevention of ventilator-induced lung edema by inhalation of nanoparticles releasing ruthenium red. Am. J. Respir. Cell Mol. Biol., 2014, 50, 1107-1117.
88. Das, J.; Das, S.; Paul, A.; Samadder, A.; Bhattacharyya, S.S.; Khuda-Bukhsh, A.R. Assessment of drug delivery and anticancer potentials of nanoparticles-loaded siRNA targeting STAT3 in lung cancer, in vitro and in vivo. Toxicol. Lett., 2014, 225, 454-466.
89. Nguyen, J.; Steele, T.W.; Merkel, O.; Reul, R.; Kissel, T. Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. J. Control Release, 2008, 132, 243-251.
90. Dailey, L.A.; Kleemann, E.; Wittmar, M.; Gessler, T.; Schmehl, T.; Roberts, C.; Seeger, W.; Kissel, T. Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA. Pharm. Res., 2003, 20, 2011-2020.
91. Beck-Broichsitter, M.; Kleimann, P.; Schmehl, T.; Betz, T.; Bakowsky, U.; Kissel, T.; Seeger, W. Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers. Eur. J. Pharm. Biopharm., 2012, 82, 272-280.
92. Jensen, D.K.; Jensen, L.B.; Koocheki, S.; Bengtson, L.; Cun, D.; Nielsen, H.M.; Foged, C. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J. Control Release, 2012, 157, 141-148.
93. Grenha, A.; Seijo, B.; Remunan-Lopez, C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci., 2005, 25, 427-437.
94. Muttil, P.; Prego, C.; Garcia-Contreras, L.; Pulliam, B.; Fallon, J.K.; Wang, C.; Hickey, A.J.; Edwards, D. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J., 2010, 12, 330-337.
95. Tsapis, N.; Bennett, D.; Jackson, B.; Weitz, D.A.; Edwards, D.A. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl. Acad. Sci. U. S. A, 2002, 99, 12001-12005.
96. Sung, J.C.; Padilla, D.J.; Garcia-Contreras, L.; Verberkmoes, J.L.; Durbin, D.; Peloquin, C.A.; Elbert, K.J.; Hickey, A.J.; Edwards, D.A. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm. Res., 2009, 26, 1847-1855.
97. Gomez-Gaete, C.; Fattal, E.; Silva, L.; Besnard, M.; Tsapis, N. Dexamethasone acetate encapsulation into Trojan particles. J. Control Release, 2008, 128, 41-49.
98. Pilcer, G.; Amighi, K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm., 2010, 392, 1-19.
99. Wills, P.J. Inhaled mannitol in cystic fibrosis. Expert Opin. Investig. Drugs, 2007, 16, 1121-1126.
100. Kawashima, Y.; Yamamoto, H.; Takeuchi, H.; Fujioka, S.; Hino, T. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J. Control Release, 1999, 62, 279-287.
101. Tomoda, K.; Ohkoshi, T.; Hirota, K.; Sonavane, G.S.; Nakajima, T.; Terada, H.; Komuro, M.; Kitazato, K.; Makino, K. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf. B Biointerfaces, 2009, 71, 177-182.
102. Tomoda, K.; Ohkoshi, T.; Kawai, Y.; Nishiwaki, M.; Nakajima, T.; Makino, K. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles. Colloids Surf. B Biointerfaces, 2008, 61, 138-144.
103. Tomoda, K.; Ohkoshi, T.; Nakajima, T.; Makino, K. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf. B Biointerfaces, 2008, 64, 70-76.
104. Nel, A.; Xia, T.; Madler, L.; Li, N. Toxic potential of materials at the nanolevel. Science, 2006, 311, 622-627.
105. Limbach, L.K.; Wick, P.; Manser, P.; Grass, R.N.; Bruinink, A.; Stark, W.J. Exposure of engineered nanoparticles to human lung epithelial cells: influence of chemical composition and catalytic activity on oxidative stress. Environ. Sci. Technol., 2007, 41, 4158-4163.
106. Bhattacharya, K.; Davoren, M.; Boertz, J.; Schins, R.P.; Hoffmann, E.; Dopp, E. Titanium dioxide nanoparticles induce oxidative stress and DNA-adduct formation but not DNA-breakage in human lung cells. Part Fibre. Toxicol., 2009, 6, 17.
107. Rogueda, P.G.; Traini, D. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Expert Opin. Drug Deliv., 2007, 4, 595-606.
108. Bur, M.; Lehr, C.M. Pulmonary cell culture models to study the safety and efficacy of innovative aerosol medicines. Expert Opin. Drug Deliv., 2008, 5, 641-652.
109. Grabowski, N.; Hillaireau, H.; Vergnaud, J.; Santiago, L.A.; Kerdine-Romer, S.; Pallardy, M.; Tsapis, N.; Fattal, E. Toxicity of surface-modified PLGA nanoparticles toward lung alveolar epithelial cells. Int. J. Pharm., 2013, 454, 686-694.
110. Mrakovcic, M.; Absenger, M.; Riedl, R.; Smole, C.; Roblegg, E.; Frohlich, L.F.; Frohlich, E. Assessment of long-term effects of nanoparticles in a microcarrier cell culture system. PLoS One, 2013, 8, e56791.
111. Singh, R.P.; Ramarao, P. Accumulated polymer degradation products as effector molecules in cytotoxicity of polymeric nanoparticles. Toxicol. Sci., 2013, 136, 131-143.
112. Ong, H.X.; Traini, D.; Cipolla, D.; Gonda, I.; Bebawy, M.; Agus, H.; Young, P.M. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm. Res., 2012, 29, 3335-3346.
113. Randell, S.H.; Fulcher, M.L.; O'Neal, W.; Olsen, J.C. Primary epithelial cell models for cystic fibrosis research. Methods Mol. Biol., 2011, 742, 285-310.
114. Fulcher, M.L.; Randell, S.H. Human nasal and tracheo-bronchial respiratory epithelial cell culture. Methods Mol. Biol., 2013, 945, 109-121.
115. Bur, M.; Rothen-Rutishauser, B.; Huwer, H.; Lehr, C.M. A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations. Eur. J. Pharm. Biopharm., 2009, 72, 350-357.
116. Hein, S.; Bur, M.; Kolb, T.; Muellinger, B.; Schaefer, U.F.; Lehr, C.M. The Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) in vitro system: design and experimental protocol. Altern. Lab Anim, 2010, 38, 285-295.
117. Dailey, L.A.; Jekel, N.; Fink, L.; Gessler, T.; Schmehl, T.; Wittmar, M.; Kissel, T.; Seeger, W. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol. Appl. Pharmacol., 2006, 215, 100-108.
118. Hara, K.; Tsujimoto, H.; Huang, C.C.; Kawashima, Y.; Ando, R.; Kusuoka, O.; Tamura, K.; Tsutsumi, M. Ultrastructural and Immunohistochemical Studies on Uptake and Distribution of FITCConjugated PLGA Nanoparticles Administered Intratracheally in Rats. J. Toxicol. Pathol., 2012, 25, 19-26.
119. Pourshahab, P.S.; Gilani, K.; Moazeni, E.; Eslahi, H.; Fazeli, M.R.; Jamalifar, H. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid. J. Microencapsul., 2011, 28, 605-613.
120. Sinsuebpol, C.; Chatchawalsaisin, J.; Kulvanich, P. Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Devel. Ther., 2013, 7, 861-873.
121. Sharma, K.; Somavarapu, S.; Colombani, A.; Govind, N.; Taylor, K.M. Crosslinked chitosan nanoparticle formulations for delivery from pressurized metered dose inhalers. Eur. J. Pharm. Biopharm., 2012, 81, 74-81.
122. Trivedi, R.; Redente, E.F.; Thakur, A.; Riches, D.W.; Kompella, U.B. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology., 2012, 23, 505101.
123. Sinha, B.; Mukherjee, B.; Pattnaik, G. Poly-lactide-co-glycolide nanoparticles containing voriconazole for pulmonary delivery: in vitro and in vivo study. Nanomedicine., 2013, 9, 94-104.
124. Wanakule, P.; Liu, G.W.; Fleury, A.T.; Roy, K. Nano-inside-micro: Disease-responsive microgels with encapsulated nanoparticles for intracellular drug delivery to the deep lung. J. Control Release, 2012, 162, 429-437.
125. Suk, J.S.; Kim, A.J.; Trehan, K.; Schneider, C.S.; Cebotaru, L.; Woodward, O.M.; Boylan, N.J.; Boyle, M.P.; Lai, S.K.; Guggino, W.B.; Hanes, J. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J. Control Release, 2014, 178, 8-17.
126. Rytting, E.; Bur, M.; Cartier, R.; Bouyssou, T.; Wang, X.; Kruger, M.; Lehr, C.M.; Kissel, T. In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. J. Control Release, 2010, 141, 101-107.
127. Cheow, W.S.; Ng, M.L.; Kho, K.; Hadinoto, K. Spray-freezedrying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. Int. J. Pharm., 2011, 404, 289-300.
128. Ali, M.E.; Lamprecht, A. Spray freeze drying for dry powder inhalation of nanoparticles. Eur. J. Pharm. Biopharm., 2014, 87, 510-517.
129. Yang, Y.; Cheow, W.S.; Hadinoto, K. Dry powder inhaler formulation of lipid-polymer hybrid nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier particles. Int. J. Pharm., 2012, 434, 49-58.